» Articles » PMID: 35078193

Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study

Abstract

Background: Monogenic and polygenic inheritances are evidenced for idiopathic pulmonary fibrosis (IPF). Pathogenic variations in surfactant protein-related genes, telomere-related genes (TRGs), and a single-nucleotide polymorphism in the promoter of MUC5B gene encoding mucin 5B (rs35705950 T risk allele) are reported. This French-Greek collaborative study, Gen-Phen-Re-GreekS in inheritable IPF (iIPF), aimed to investigate genetic components and patients' characteristics in the Greek national IPF cohort with suspected heritability.

Patients And Methods: 150 patients with familial PF, personal-family extrapulmonary disease suggesting short telomere syndrome, and/or young age IPF were analyzed.

Results: MUC5B rs35705950 T risk allele was detected in 103 patients (90 heterozygous, 13 homozygous, allelic frequency of 39%), monoallelic TRG pathogenic variations in 19 patients (8 TERT, 5 TERC, 2 RTEL1, 2 PARN, 1 NOP10, and 1 NHP2), and biallelic ABCA3 pathogenic variations in 3. Overlapping MUC5B rs35705950 T risk allele and TRG pathogenic variations were shown in 11 patients (5 TERT, 3 TERC, 1 PARN, 1 NOP10, and 1 NHP2), MUC5B rs35705950 T risk allele, and biallelic ABCA3 pathogenic variations in 2. In 38 patients, neither MUC5B rs35705950 T risk allele nor TRG pathogenic variations were detectable. Kaplan-Meier curves showed differences in time-to-death (p = 0.025) where patients with MUC5B rs35705950 T risk allele alone or in combination with TRG pathogenic variations presented better prognosis.

Conclusion: The Gen-Phen-Re-GreekS in iIPF identified multiple and overlapping genetic components including the rarest, underlying disease's genetic "richesse," complexity and heterogeneity. Time-to-death differences may relate to diverse IPF pathogenetic mechanisms implicating "personalized" medical care driven by genotypes in the near future.

Citing Articles

Clinical, radiological and histopathological features of patients with familial pulmonary fibrosis.

Jaula H, Mattila L, Lappi-Blanco E, Salonen J, Vahanikkila H, Ahvenjarvi L Respir Res. 2024; 25(1):239.

PMID: 38867203 PMC: 11170837. DOI: 10.1186/s12931-024-02864-5.


Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.

Adegunsoye A, Kropski J, Behr J, Blackwell T, Corte T, Cottin V Am J Respir Crit Care Med. 2024; 210(4):401-423.

PMID: 38573068 PMC: 11351799. DOI: 10.1164/rccm.202401-0238SO.


Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?.

Tomos I, Roussis I, Matthaiou A, Dimakou K Biomedicines. 2023; 11(10).

PMID: 37893169 PMC: 10604739. DOI: 10.3390/biomedicines11102796.


Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression.

Domvri K, Organtzis I, Apostolopoulos A, Fouka E, Kontakiotis T, Papakosta D J Pers Med. 2023; 13(9).

PMID: 37763075 PMC: 10532947. DOI: 10.3390/jpm13091307.


Genomic Fingerprint Associated with Familial Idiopathic Pulmonary Fibrosis: A Review.

Ding D, Gao R, Xue Q, Luan R, Yang J Int J Med Sci. 2023; 20(3):329-345.

PMID: 36860670 PMC: 9969503. DOI: 10.7150/ijms.80358.